The recombinant Rhesus monkey IL1RAP is a well-characterized protein with defined molecular properties. When expressed in human embryonic kidney (HEK293) cells with a His-tag at the C-terminus, the protein spans from Met1 to Glu359, comprising 350 amino acids with a calculated molecular mass of 40.56 kDa . The protein shares significant homology with human IL1RAP, making it valuable for comparative studies of interleukin signaling across primate species.
IL1RAP belongs to the interleukin-1 receptor family and features characteristic structural domains:
An extracellular domain containing immunoglobulin-like regions responsible for ligand interaction
A transmembrane domain anchoring the protein to the cell membrane
An intracellular Toll/IL-1R (TIR) domain essential for signal transduction
The protein exists in multiple isoforms resulting from alternative splicing, with both membrane-bound and soluble variants that differ in their C-terminal regions . The ratio of soluble to membrane-bound forms increases notably during acute-phase responses or stress conditions, suggesting a regulatory mechanism for IL-1 signaling .
Recombinant Rhesus monkey IL1RAP is typically produced in mammalian expression systems to ensure proper folding and post-translational modifications. The protein is commonly expressed with His-tags or other fusion partners to facilitate purification. The production specifications for commercially available recombinant IL1RAP include:
| Parameter | Specification |
|---|---|
| Expression System | HEK293 cells |
| Fusion Tag | His (C-terminal) |
| Protein Length | Met1-Glu359 |
| Molecular Mass | 40.56 kDa |
| Form | Lyophilized from sterile PBS, pH 7.4 |
| Purity | >90% as determined by SDS-PAGE |
| Endotoxin Level | <1.0 EU per μg protein |
Table 1: Properties of Recombinant Rhesus monkey IL1RAP protein
IL1RAP serves as a critical co-receptor in the IL-1 signaling pathway. It does not bind to interleukin-1 directly but associates with IL1R1 that has bound IL1B to form a high-affinity receptor complex . This complex formation is necessary for efficient signal transduction and subsequent activation of downstream pathways including NF-kappa-B activation . The signaling cascade involves:
Initial binding of IL-1 to IL-1R1
Recruitment of IL1RAP to form a heterotrimeric complex
Conformational changes in the cytoplasmic TIR domains
Recruitment of adapter molecules including TOLLIP, MYD88, and IRAK1/2
Activation of downstream kinases and transcription factors
Induction of pro-inflammatory gene expression
The protein exhibits remarkable specificity in its co-receptor functions, showing strong interactions with multiple interleukin receptor family members as evidenced by high STRING interaction scores .
Beyond the canonical IL-1 pathway, IL1RAP also functions as a co-receptor for IL1RL2 in the IL-36 signaling system . This versatility points to IL1RAP's broader role in coordinating various inflammatory signals. The protein's function extends to multiple signaling networks that collectively regulate inflammation, immune cell activation, and tissue homeostasis.
STRING database analysis reveals the extensive protein interaction network of Macaca mulatta IL1RAP, highlighting its central role in inflammatory signaling cascades. The protein shows particularly strong interactions with multiple components of the interleukin signaling system:
| Interaction Partner | Description | Interaction Score |
|---|---|---|
| IL1B | Interleukin-1 beta | 0.981 |
| IL33 | Interleukin-33 | 0.977 |
| IL1R1 | Interleukin 1 receptor type 1 | 0.967 |
| IL1RL1 | Interleukin 1 receptor like 1 | 0.960 |
| IL1R2 | Interleukin 1 receptor type 2 | 0.941 |
| IL1RL2 | Interleukin 1 receptor like 2 | 0.930 |
| PTPRD | Protein tyrosine phosphatase receptor type D | 0.922 |
| PTPRS | Protein tyrosine phosphatase receptor type S | 0.858 |
| IL1A | Interleukin-1 alpha | 0.841 |
| MYD88 | Myeloid differentiation primary response protein | 0.791 |
Table 2: Functional interaction partners of IL1RAP with confidence scores
The remarkably high interaction scores with IL1B, IL33, and IL1R1 (all above 0.96) underscore IL1RAP's central role in mediating signals from multiple interleukin family members. The interaction with MYD88 further confirms its involvement in the canonical signaling pathway leading to NF-kappa-B activation.
IL1RAP plays a significant role in immune regulation by facilitating IL-1 signaling, which is crucial for initiating and maintaining inflammatory responses . This signaling pathway is essential for:
Activation of innate immune responses
Production of pro-inflammatory cytokines
Recruitment and activation of immune cells
Amplification of inflammatory cascades
Regulation of adaptive immune responses
The balance between membrane-bound and soluble IL1RAP forms contributes to the fine-tuning of these immune responses, with soluble forms potentially acting as decoy receptors to dampen excessive inflammation .
The high degree of conservation between rhesus and human IL1RAP makes the recombinant Macaca mulatta protein valuable for comparative studies. Researchers can investigate species-specific differences in IL-1 signaling pathways and test the cross-reactivity of therapeutic agents targeting IL1RAP before advancing to human studies. This approach is particularly relevant given the established use of rhesus macaques as models for human inflammatory and autoimmune conditions.
Recombinant Macaca mulatta IL1RAP has significant applications in drug discovery pipelines, particularly for the development of therapeutics targeting the IL-1 signaling pathway. These applications include:
High-throughput screening of small molecule inhibitors
Development and testing of therapeutic antibodies
Structure-based drug design targeting the IL-1 receptor complex
Validation studies for IL-1 pathway antagonists
Given IL1RAP's abnormal expression in various diseases including cancer and autoimmune disorders, it has emerged as a promising target for therapeutic intervention .
Several assays can be employed to assess the functional activity of recombinant IL1RAP:
Binding Assays: ELISA-based binding assays measuring interaction with IL-1R1 and IL-1β
Cell-Based Assays: Reporter cell lines expressing NF-κB response elements
Co-Immunoprecipitation: Verification of complex formation with IL-1R1
Surface Plasmon Resonance: Quantitative measurement of binding kinetics
Quality control for recombinant IL1RAP typically includes:
Purity assessment by SDS-PAGE (>90% purity standard)
Endotoxin testing using the LAL method (<1.0 EU per μg protein)
Functional validation through binding assays
Mass spectrometry verification of protein identity
IL1RAP demonstrates significant evolutionary conservation across primate species, reflecting the fundamental importance of IL-1 signaling in mammalian immune systems. The high degree of homology between rhesus macaque and human IL1RAP makes the recombinant protein particularly valuable for translational research.
Studies of recombinant IL1RAP from different species are important for understanding cross-reactivity of therapeutic agents. Research indicates that recombinant human IL-1α demonstrates potent behavioral effects in rhesus monkeys, suggesting a high degree of cross-species activity in the IL-1 signaling pathway . This cross-reactivity extends to the IL1RAP component of the signaling complex.
IL1RAP (Interleukin-1 Receptor Accessory Protein) serves as a critical co-receptor for IL-1α, IL-1β, and IL-33 signaling, enabling the formation of active receptor complexes that mediate pro-inflammatory responses. In rhesus macaque models, IL1RAP is essential for studying:
T follicular helper (Tfh) cell differentiation: IL1RAP modulates cytokine-driven pathways (e.g., IL-6, IP-10) that determine Tfh1 vs. Tfh17 polarization, directly influencing germinal center activity and antibody persistence .
Cross-species signaling fidelity: Rhesus IL1RAP shares 94% amino acid homology with humans, making it a robust model for translational immunology studies .
Methodological Recommendation:
To assess IL1RAP's role in immune pathways:
Use cytokine-polarized T cell cultures with recombinant IL1RAP-blocking antibodies.
Quantify IL1RAP-dependent signaling via phospho-NF-κB/STAT3 flow cytometry.
Validate using lymph node biopsies in vaccine challenge models .
Recombinant IL1RAP production for macaque research typically involves:
Expression system: E. coli (for non-glycosylated proteins) or mammalian cells (for post-translational modifications).
Tagging: N-terminal 6xHis-SUMO tags improve solubility and purification yields .
Quality control: SDS-PAGE (>90% purity) and endotoxin testing (<1 EU/μg) .
| Parameter | Specification |
|---|---|
| Host | E. coli (BL21) or HEK293 cells |
| Vector | pET-28a(+) or pcDNA3.1 |
| Tag | 6xHis-SUMO (N-terminal) |
| Theoretical MW | 34.1 kDa (unmodified) |
| Storage | -20°C in Tris/PBS + 5–50% glycerol |
IHC/IF: Use rabbit polyclonal anti-IL1RAP (NBP2-16946) with pan-cytokeratin counterstaining to localize IL1RAP in epithelial vs. immune cells .
ELISA: Commercial kits (e.g., Biomatik RPC21509) detect IL1RAP at sensitivities of 0.1–50 ng/mL .
Flow cytometry: Phycoerythrin-conjugated anti-IL1RAP antibodies (clone 3C10) for cell-surface staining.
Critical Note: Cross-reactivity with human IL1RAP antibodies is >95% but requires validation via Western blot using recombinant macaque IL1RAP standards .
Adjuvant pairing: IL1RAP inhibition with MPLA+QS-21 enhances Tfh1 polarization, increasing Env antibody persistence by 2.5-fold compared to CAF01-adjuvanted vaccines .
Cytokine engineering: DNA primes encoding IP-10/IL-6 synergize with IL1RAP blockade to prolong germinal center reactions (30-week antibody retention vs. 8-week in controls) .
Antibody-dependent cytotoxicity: Defucosylated anti-IL1RAP mAbs (e.g., CAN04) enhance ADCC by 40% in PDAC xenografts .
Chemotherapy synergy: CAN04 + platinum agents reduce IL-6/CRP levels by 60%, overcoming IL1-driven chemoresistance .
| Application | Strategy | Key Outcome | Source |
|---|---|---|---|
| HIV Vaccination | MPLA+QS-21 + IP-10 DNA prime | 5,500 ng/mL gp140 IgG at 30 weeks | |
| Pancreatic Cancer | CAN04 (10 mg/kg) + Cisplatin | 43% stable disease; CRP ↓ 72% |
Common conflicts arise from:
Ligand bias: IL-1α vs. IL-1β activate distinct IL1RAP conformational states, altering downstream NF-κB/AP-1 ratios.
Model divergence: Murine IL1RAP lacks the IL-33 binding domain present in primates, limiting translational relevance .
Pathway-specific reporters: Use luciferase-NF-κB/STAT3 constructs in HEK-IL1R1/IL1RAP cells.
Ligand titration: Test IL-1α (EC50 = 0.57 μg/mL) vs. IL-1β (EC50 = 0.60 μg/mL) in blockade assays .
Single-cell RNA-seq: Profile IL1RAP+ Tfh subsets in macaque lymph nodes post-vaccination .
LN biopsy timing: Sample at 3 weeks post-boost for peak GC Tfh activity (CD4+CXCR5+PD-1+) .
Multiparametric cytometry: Panel: CD3/CD4/CXCR5/BCL-6/IL-21/IFN-γ/IL-17A.
Tiered neutralization assays: Measure ID50 against HIV-1 pseudoviruses to correlate Tfh1 frequency with antibody potency .
Data Interpretation Tip: Tfh1 dominance (IFN-γ+ >60%) predicts 4-fold higher neutralization breadth compared to Tfh17-skewed responses .
Step 1: Screen FFPE archives using IL1RAP IHC (H-score ≥200 correlates with CAN04 response) .
Step 2: Validate soluble IL1RAP (sIL1RAP) via Meso Scale Discovery electrochemiluminescence.
Step 3: Correlate sIL1RAP with IL-6 (r = 0.82, p < 0.01) and CRP (r = 0.79, p < 0.01) in serial serum samples .
| Biomarker | Baseline (Mean) | Post-Treatment (Δ) | p-value |
|---|---|---|---|
| IL-6 | 18.2 pg/mL | -62% | 0.003 |
| CRP | 12.4 mg/L | -71% | 0.001 |
| sIL1RAP | 4.3 ng/mL | +220% | 0.02 |
Compensatory signaling: IL-33 upregulation occurs in 30% of CAN04-treated tumors, requiring dual IL1RAP/ST2 blockade .
Tfh plasticity: Vaccine-induced Tfh1 cells transiently express IL1RAP (48–72 hr window), necessitating timed booster schedules .
Species-specific ADCC: CAN04’s defucosylated Fc has 90% ADCC in human PBMCs but only 35% activity in macaques .
IL1RAP crystallography: Murine-human chimeric receptors resolve macaque-specific epitopes for antibody engineering.
In vivo CRISPR: Macaque IL1RAP KO models validate on-target/off-immune effects of therapeutic mAbs.